Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Nicholas Papadopoulos

Showing results (21-30 of 34) with videos related to

Pageof 4
Sort By:
Nature Cancer|February 5, 2022
Author Correction: Targeting public neoantigens for cancer immunotherapyAlexander H Pearlman, Michael S Hwang, Maximilian F Konig, et al.
Nature Cancer|October 22, 2021
Targeting public neoantigens for cancer immunotherapyAlexander H Pearlman, Michael S Hwang, Maximilian F Konig, et al.
Proceedings of the National Academy of Sciences of the United States of America|April 8, 2014
Mice with megabase humanization of their immunoglobulin genes generate antibodies as efficiently as normal miceAndrew J Murphy, Lynn E Macdonald, Sean Stevens, et al.
Scientific Reports|December 15, 2015
A novel, native-format bispecific antibody triggering T-cell killing of B-cells is robustly active in mouse tumor models and cynomolgus monkeysEric J Smith, Kara Olson, Lauric J Haber, et al.
Molecular Cancer Therapeutics|August 13, 2009
Activity of dasatinib against L576P KIT mutant melanoma: molecular, cellular, and clinical correlatesScott E Woodman, Jonathan C Trent, Katherine Stemke-Hale, et al.
ESMO Open|February 2, 2018
Retrospective review of metastatic melanoma patients with leptomeningeal disease treated with intrathecal interleukin-2Isabella C Glitza, Michelle Rohlfs, Nandita Guha-Thakurta, et al.
Bioorganic & Medicinal Chemistry|April 2, 2018
Antibody drug conjugates of cleavable amino-alkyl and aryl maytansinoidsThomas Nittoli, Marcus P Kelly, Frank Delfino, et al.
Angiogenesis|May 29, 2016
Aflibercept exhibits VEGF binding stoichiometry distinct from bevacizumab and does not support formation of immune-like complexesDouglas A MacDonald, Joel Martin, Kathir K Muthusamy, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 3, 2011
Impact of clinical and pathologic features on tumor-infiltrating lymphocyte expansion from surgically excised melanoma metastases for adoptive T-cell therapyRichard W Joseph, Vijay R Peddareddigari, Ping Liu, et al.
JAMA Oncology|October 18, 2019
Circulating Tumor DNA Analyses as Markers of Recurrence Risk and Benefit of Adjuvant Therapy for Stage III Colon CancerJeanne Tie, Joshua D Cohen, Yuxuan Wang, et al.
Pageof 4

Showing results (21-30 of 34) with videos related to

Sort By:
Pageof 4
Nature Cancer|February 5, 2022
Author Correction: Targeting public neoantigens for cancer immunotherapyAlexander H Pearlman, Michael S Hwang, Maximilian F Konig, et al.
Nature Cancer|October 22, 2021
Targeting public neoantigens for cancer immunotherapyAlexander H Pearlman, Michael S Hwang, Maximilian F Konig, et al.
Proceedings of the National Academy of Sciences of the United States of America|April 8, 2014
Mice with megabase humanization of their immunoglobulin genes generate antibodies as efficiently as normal miceAndrew J Murphy, Lynn E Macdonald, Sean Stevens, et al.
Scientific Reports|December 15, 2015
A novel, native-format bispecific antibody triggering T-cell killing of B-cells is robustly active in mouse tumor models and cynomolgus monkeysEric J Smith, Kara Olson, Lauric J Haber, et al.
Molecular Cancer Therapeutics|August 13, 2009
Activity of dasatinib against L576P KIT mutant melanoma: molecular, cellular, and clinical correlatesScott E Woodman, Jonathan C Trent, Katherine Stemke-Hale, et al.
ESMO Open|February 2, 2018
Retrospective review of metastatic melanoma patients with leptomeningeal disease treated with intrathecal interleukin-2Isabella C Glitza, Michelle Rohlfs, Nandita Guha-Thakurta, et al.
Bioorganic & Medicinal Chemistry|April 2, 2018
Antibody drug conjugates of cleavable amino-alkyl and aryl maytansinoidsThomas Nittoli, Marcus P Kelly, Frank Delfino, et al.
Angiogenesis|May 29, 2016
Aflibercept exhibits VEGF binding stoichiometry distinct from bevacizumab and does not support formation of immune-like complexesDouglas A MacDonald, Joel Martin, Kathir K Muthusamy, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 3, 2011
Impact of clinical and pathologic features on tumor-infiltrating lymphocyte expansion from surgically excised melanoma metastases for adoptive T-cell therapyRichard W Joseph, Vijay R Peddareddigari, Ping Liu, et al.
JAMA Oncology|October 18, 2019
Circulating Tumor DNA Analyses as Markers of Recurrence Risk and Benefit of Adjuvant Therapy for Stage III Colon CancerJeanne Tie, Joshua D Cohen, Yuxuan Wang, et al.
Pageof 4